Onkologie. 2020:14(4):148-156 | DOI: 10.36290/xon.2020.057

Comprehensive treatment of early breast cancer

Vlastimila Čmejlová
Onkologické oddělení FN Motol, Praha

The aim of comprehensive treatment of breast cancer is the permanent cure of the patient and the elimination of micrometastases. Treatment includes surgery, systemic adjuvant / neoadjuvant treatment, and radiotherapy. Patients receive cytostatic treatment, targeted therapy, and/or hormonal therapy. Subsequently, radiotherapy is indicated according to the extent of surgery and definitive histological examination. Prior to initiation of therapy, histological verification and assessment of the extent of the disease must be performed with all basic predictive and prognostic factors determined. Assessment of the disease state by a multidisciplinary team is essential to select the optimal treatment, obtain maximum benefit and minimize risks.

Keywords: early breast cancer, adjuvant and neoadjuvant treatment, target therapy, surgery, radiotherapy.

Published: September 23, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čmejlová V. Comprehensive treatment of early breast cancer. Onkologie. 2020;14(4):148-156. doi: 10.36290/xon.2020.057.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Modrá kniha České onkologické společnosti 2020. ISBN: 978-80-86793-49-8.
    2. Novotný J, Vítek P, Kleibl Z, et al. Onkologie v klinické praxi. Standardní přístupy v diagnostice a léčbě vybraných zhoubných nádorů 2019. Praha: Mladá fronta, 2019: 640 s.
    3. NCCN (National Cancer Comprehensive Network) https://www.nccn.org/
    4. ESMO (European School of Medical Oncology) ttps://www.esmo.org/guidelines/breast-cancer.
    5. MSKCC( Memorial Sloan-Kettering Cancer Center) Nomograms.mskcc.org/breast/DuctalCarcinomaInSituRecurrencePage.aspx.
    6. Vieira AF, Schmitt F. An Update on Breast Cancer Multigene Prognostic Tests - Emergent Clinical Biomarkers.Published online 2018 Sep 4. doi: 10.3389/fmed.2018.00248. Go to original source... Go to PubMed...
    7. Cameron D, Piccart-Gebhart M, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial February 16, 2017 https://doi.org/10.1016/S0140-6736(16)32616-2. Go to original source... Go to PubMed...
    8. Kristeleit H, et al. Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Target Oncol. 2016; 11(5): 579-591. Published online 2016 May 16. doi: 10.1007/s11523-016-0438-5. Go to original source... Go to PubMed...
    9. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Annals of Oncology 29: 2328-2333, 2018 doi:10.1093/annonc/mdy414 Published online 13 September 2018. Go to original source... Go to PubMed...
    10. Goodman A. APHINITY Update Supports Benefit of Pertuzumab-Based Triplet in Early HER2-Positive, Node-Positive Breast Cancer January 25, 2020 The ASCO POST.
    11. Davies Ch, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Dr Christina Davies, MBChB, et al. Published: December 05, 2012. doi: https://doi.org/10.1016/S0140-6736(12)61963-1. Go to original source... Go to PubMed...
    12. Francis P, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancor Prudence A. Francis et al. N Engl J Med 2018; 379: 122-137. doi: 10.1056/NEJMoa1803164. Go to original source... Go to PubMed...
    13. Cuzick J. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial The Lancet Oncology Published: November 17, 2010. doi: https://doi.org/10.1016/S1470-2045(10)70257-6. Go to original source... Go to PubMed...
    14. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol, 2015; 33: 13. Go to original source...
    15. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15(7): 747-756. Go to original source...
    16. Untch M, von Minckwitz G. GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol. 2018; 36(13): 1308-1316. doi: 10.1200/JCO.2017.75.9175. Epub 2018. Go to original source... Go to PubMed...
    17. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010; 375: 377. Go to original source...
    18. Ismael G, et al Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012; 13(9): 869-878. doi: 10.1016/S1470-2045(12)70329-7. Epub 2012 Aug 9. Go to original source... Go to PubMed...
    19. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicenter, open-label, phase 2 trial. Lancet Oncol 2012; 13(1): 25-32. Go to original source...
    20. Schneeweiss A, et al Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018; 89: 27-35. doi: 10.1016/j.ejca.2017.10.021. Epub 2017 Dec 8. Go to original source... Go to PubMed...
    21. Baselga J, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial. Lancet 2012; 379(9816): 633-640. Go to original source...
    22. Ellis MJ, et al. ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. DOI: 10.1200/jco.2010.28.18_suppl.lba513 Journal of Clinical Oncology 28, no. 18_suppl. Go to original source...
    23. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017; 318(10): 918-926. Go to original source... Go to PubMed...
    24. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14(7): 609-618. Go to original source...
    25. SABCS 2018: AMAROS Trial: 10-Year Follow-up of Axillary Radiotherapy or Surgery in Early-Stage Breast Cancer By The ASCO Post.
    26. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumabbased adjuvant therapy in HER2-positive breast cancer (ExteNET): 5year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18(12): 1688-1700. Go to original source...
    27. von Minckwitz G, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (KATHERINE) N Engl J Med 2019; 380: 617-628. doi:0.1056/NEJMoa1814017. Go to original source... Go to PubMed...
    28. Masuda N.Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy N Engl J Med 2017; 376: 2147-2159. doi: 10.1056/NEJMoa1612645. Go to original source... Go to PubMed...
    29. Galimberti, V Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial The Lancet Oncology mailto:viviana.galimberti@ieo.itPublished:September 05, 2018. doi: https://doi.org/10.1016/S1470-2045(18)30380-2. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.